Turn Therapeutics direct listing
We advised Turn Therapeutics on its Nasdaq listing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Oruka Therapeutics $200 million at-the-market offering
We advised Oruka on the offering
Medtronic €1.5 billion notes offering
The investment-grade notes are due 2030 and 2045
MBX Biosciences $200 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Laekna HK$587 million placement of shares
We advised Laekna on the placement of new shares
Strive acquisition of Semler Scientific
We are advising Strive on the acquisition
Oruka Therapeutics $180 million private placement
The PIPE included common stock and pre-funded warrants
GenFleet Therapeutics HK$1.82 billion IPO
We advised GenFleet on its IPO and HKEX listing
Oscar Health $410 million convertible senior subordinated notes and capped call transactions
The 2.25% convertible notes are due 2030
Royalty Pharma $2 billion senior notes offering
We advised Royalty Pharma on its investment-grade notes offering